US 7,537,930 B2
	Mammalian cell lines for increasing longevity and protein yield from a cell culture
David M. Goldenberg, Mendham, N.J. (US); Zhengxing Qu, Warren, N.J. (US); Chien Hsing Chang, Downingtown, Pa. (US); Edmund A. Rossi, Nutley, N.J. (US); Jeng-Dar Yang, Bedminster, N.J. (US); and Diane Nordstrom, Rockaway, N.J. (US)
Assigned to Immunomedics, Inc., Morris Plains, N.J. (US)
Filed on Jul. 14, 2006, as Appl. No. 11/487,215.
Application 11/487215 is a continuation in part of application No. 11/187863, filed on Jul. 25, 2005.
Claims priority of provisional application 60/590349, filed on Jul. 23, 2004.
Prior Publication US 2007/0015250 A1, Jan. 18, 2007
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/00 (2006.01); C12P 21/00 (2006.01); C12N 15/00 (2006.01)

U.S. Cl. 435—325  [435/70.1; 435/455]

12 Claims

1. A mammalian cell line that is transfected with an inhibitor of apoptosis comprising a gene encoding Bcl-2 with T69E, S70E and S87E mutations (Bcl-EEE) and adapted to grow in serum-free medium, the cell line transfectable with one or more expression vectors under serum-free conditions, wherein the gene encoding Bcl-EEE has a nucleotide sequence of SEQ ID NO:3.